MX357060B - Derivados de 2,2-difluoropropionamida de bardoxolon metilo, formas polimorficas y metodo para su uso de los mismos. - Google Patents

Derivados de 2,2-difluoropropionamida de bardoxolon metilo, formas polimorficas y metodo para su uso de los mismos.

Info

Publication number
MX357060B
MX357060B MX2014013076A MX2014013076A MX357060B MX 357060 B MX357060 B MX 357060B MX 2014013076 A MX2014013076 A MX 2014013076A MX 2014013076 A MX2014013076 A MX 2014013076A MX 357060 B MX357060 B MX 357060B
Authority
MX
Mexico
Prior art keywords
methods
polymorphic forms
bardoxolone methyl
difluoropropionamide
derivatives
Prior art date
Application number
MX2014013076A
Other languages
English (en)
Other versions
MX2014013076A (es
Inventor
Anderson Eric
Decker Andrea
Liu Xiaofeng
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of MX2014013076A publication Critical patent/MX2014013076A/es
Publication of MX357060B publication Critical patent/MX357060B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere generalmente al compuesto: N-((4aS,6aR,6bS,8aR, 12aS,14aR,14bS)-1 1-ciano-2,2,6a,6b,9,9,12a-h eptametil-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a ,14b-octadecahidropicen-4a-il)-2,2-difluoropropanamida, formas polimórficas del mismo, método para la preparación y uso del mismo, composiciones farmacéuticas del mismo, y equipos y artículos para la elaboración del mismo.
MX2014013076A 2012-04-27 2013-04-24 Derivados de 2,2-difluoropropionamida de bardoxolon metilo, formas polimorficas y metodo para su uso de los mismos. MX357060B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261687669P 2012-04-27 2012-04-27
US201361775288P 2013-03-08 2013-03-08
US201361780444P 2013-03-13 2013-03-13
PCT/US2013/038064 WO2013163344A1 (en) 2012-04-27 2013-04-24 2.2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2014013076A MX2014013076A (es) 2015-05-11
MX357060B true MX357060B (es) 2018-06-25

Family

ID=49483867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013076A MX357060B (es) 2012-04-27 2013-04-24 Derivados de 2,2-difluoropropionamida de bardoxolon metilo, formas polimorficas y metodo para su uso de los mismos.

Country Status (36)

Country Link
US (4) US8993640B2 (es)
EP (2) EP2841445B1 (es)
JP (2) JP6410710B2 (es)
KR (1) KR102101774B1 (es)
CN (1) CN104395332B (es)
AR (1) AR092823A1 (es)
AU (1) AU2013251602B2 (es)
BR (1) BR112014026640B1 (es)
CA (1) CA2869783C (es)
CL (1) CL2014002886A1 (es)
CO (1) CO7170182A2 (es)
CY (2) CY1119333T1 (es)
DK (2) DK2841445T3 (es)
DO (1) DOP2014000236A (es)
EA (1) EA030468B1 (es)
ES (2) ES2861393T3 (es)
HK (2) HK1207086A1 (es)
HR (1) HRP20171275T1 (es)
HU (2) HUE053113T2 (es)
IL (1) IL235275B (es)
LT (2) LT2841445T (es)
ME (1) ME02926B (es)
MX (1) MX357060B (es)
MY (1) MY172750A (es)
NZ (1) NZ630222A (es)
PE (1) PE20150160A1 (es)
PL (2) PL3444261T3 (es)
PT (2) PT2841445T (es)
RS (2) RS56154B1 (es)
SG (1) SG11201406868XA (es)
SI (2) SI3444261T1 (es)
TW (2) TWI623548B (es)
UA (1) UA116209C2 (es)
UY (1) UY34764A (es)
WO (1) WO2013163344A1 (es)
ZA (1) ZA201407326B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4923146B2 (ja) 2008-01-11 2012-04-25 リアタ ファーマシューティカルズ インコーポレイテッド 合成トリテルペノイドおよび疾患の治療における使用方法
MX2010011438A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Antioxidantes moduladores de la inflamacion: derivados del acido oleanólico con amino y otras modificaciones en c-17.
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
NO2651902T3 (es) 2010-12-17 2018-04-07
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
ES2861393T3 (es) 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
EA029174B1 (ru) 2012-09-10 2018-02-28 Рита Фармасьютикалз, Инк. C17-алкандиильные и алкендиильные производные олеаноловой кислоты и способы их применения
UY35534A (es) 2013-04-24 2014-10-31 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
EP3212195A4 (en) 2014-10-31 2018-06-06 The Regents of The University of California Compositions and methods for treating hiv-associated cognitive dysfunction
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
JP6633812B2 (ja) 2016-11-08 2020-01-22 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
CN110248932B (zh) 2016-12-16 2023-03-10 里亚塔医药公司 用于抑制RORγ和其他用途的嘧啶三环烯酮衍生物
WO2019227055A1 (en) * 2018-05-24 2019-11-28 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
JP7212763B2 (ja) 2018-08-20 2023-01-25 ヤンセン ファーマシューティカ エヌ．ベー． ＫＥＡＰ１－Ｎｒｆ２タンパク質－タンパク質相互作用の阻害剤
US20220133748A1 (en) * 2019-02-15 2022-05-05 Triterpenoid Therapeutics, Inc. Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
EP4069287A4 (en) * 2019-12-03 2023-11-22 Baylor College of Medicine THERAPEUTIC COMPOUNDS FOR USE IN INSULIN RESISTANCE
AU2021397631A1 (en) 2020-12-11 2023-07-20 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN117015548A (zh) * 2021-01-18 2023-11-07 里亚塔医药公司 合成的熊果酸衍生物和其使用方法
CN113197905B (zh) * 2021-04-23 2022-04-19 浙江大学 三萜类化合物在制备神经母细胞瘤治疗药物中的应用
CN113358627B (zh) * 2021-06-23 2022-07-01 华中农业大学 一种基于拉曼检测的田间快速测定茶树品质成分的方法
CN114344308A (zh) * 2021-12-22 2022-04-15 山西医科大学第二医院 甲基巴多索隆在制备防治骨关节炎的药物中的应用
EP4349847A1 (en) 2022-09-21 2024-04-10 Sicor Società Italiana Corticosteroidi S.r.l. Process and intermediates for preparation of omaveloxolone and salts thereof

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5555153Y2 (es) 1975-03-19 1980-12-20
US4395423A (en) 1978-10-10 1983-07-26 Sterling Drug Inc. Polycyclic cyanoketones
NZ191586A (en) 1978-10-10 1981-10-19 Sterling Drug Inc Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions
US5064823A (en) 1988-08-24 1991-11-12 Research Triangle Institute Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US6369101B1 (en) 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
MXPA01011613A (es) 1999-05-14 2003-10-14 Nereus Pharmaceuticals Inc Nuevos moduladores de interleucina-1 y factor-alfa de necrosis tumoral, sistesis de dichos moduladores y metodos de utilizar dichos moduladores.
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
JP2001240573A (ja) 2000-03-01 2001-09-04 Meiji Seika Kaisha Ltd トリテルペン誘導体及び肝疾患治療剤
WO2002003996A1 (en) 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Use of dammarane-type tritepenoid saporins
JP2004509972A (ja) 2000-09-29 2004-04-02 リージェンツ　オブ　ザ　ユニバーシティ　オブ　ミネソタ 酵母に対する殺真菌活性を有するトリテルペン
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
US6951847B2 (en) 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
US6878751B1 (en) 2000-10-19 2005-04-12 Imperial College Of Science Technology And Medicine Administration of resveratrol to treat inflammatory respiratory disorders
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
CA2430454A1 (en) 2000-11-28 2002-06-20 Board Of Regents, The University Of Texas System Cddo-compounds and combination therapies thereof
US20040234977A1 (en) 2001-05-14 2004-11-25 Da-Wei Gong Novel alanine transaminase enzyme and methods of use
CA2472581C (en) 2002-01-15 2012-06-26 Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
CA2473799A1 (en) 2002-01-18 2003-07-31 Regents Of The University Of Minnesota Triterpene quaternary salts as biologically active surfactants
EP1507541A4 (en) 2002-05-13 2009-06-03 Dartmouth College HEMMER AND APPLICATION METHOD THEREFOR
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
WO2005042002A2 (en) 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
WO2005046732A2 (en) 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methods and compositions for the inhibition of hiv-1 replication
US20060258752A1 (en) 2004-02-12 2006-11-16 Vander Jagt David L Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors
JP2005314381A (ja) 2004-03-30 2005-11-10 Anges Mg Inc 増殖性腎疾患の予防・治療・改善剤
EP1811840B1 (en) 2004-09-07 2016-04-13 May Sung Mak Anti-tumor compounds with angeloyl groups
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
JP2009530405A (ja) 2006-03-23 2009-08-27 アドバンスト ライフ サイエンシズ インコーポレイテッド 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体
WO2007127791A2 (en) 2006-04-25 2007-11-08 The Administrators Of The Tulane Educational Fund New pharmacological method for treatment of neuropathic pain
US8389573B2 (en) 2006-06-27 2013-03-05 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
WO2008016095A1 (fr) 2006-08-02 2008-02-07 Santen Pharmaceutical Co., Ltd. REMÈDE PRÉVENTIF OU CURATIF POUR LES KÉRATOCONJONCTIVITES CONTENANT UN ACTIVATEUR DE Nrf2 EN TANT QUE MATIÈRE ACTIVE
JP2008110962A (ja) 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
WO2008064133A1 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008064132A2 (en) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
FI2629097T1 (fi) 2007-02-08 2022-06-15 Biogen Idec Inc Nrf2-seulontatestejä ja niihin liittyviä menetelmiä ja koostumuksia
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US20080254055A1 (en) 2007-04-11 2008-10-16 John Erich Oblong Compositions for Regulation of Hair Growth
WO2008136838A1 (en) 2007-05-04 2008-11-13 Trustees Of Dartmouth College Novel amide derivatives of cddo and methods of use thereof
WO2009023845A2 (en) 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US8088824B2 (en) 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
US9012439B2 (en) 2007-10-29 2015-04-21 University Of Rochester Use of electrophilic compounds for inducing platelet production or maintaining platelet function
JP4923146B2 (ja) 2008-01-11 2012-04-25 リアタ ファーマシューティカルズ インコーポレイテッド 合成トリテルペノイドおよび疾患の治療における使用方法
JP5564490B2 (ja) 2008-04-18 2014-07-30 リアタ ファーマシューティカルズ インコーポレイテッド 抗炎症性ファルマコアを含む化合物および使用法
MX2010011439A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Moduladores de inflamacion antioxidantes: derivados del acido oleanolico homologacion c-17.
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX2010011438A (es) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Antioxidantes moduladores de la inflamacion: derivados del acido oleanólico con amino y otras modificaciones en c-17.
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
EP2362770A4 (en) 2008-11-21 2012-05-30 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE
JP5775464B2 (ja) 2009-02-13 2015-09-09 リアタ ファーマシューティカルズ，インク 非晶質ｃｄｄｏ−ｍｅを含有する遅延放出性経口投薬組成物
EP3028707A1 (en) 2009-05-01 2016-06-08 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
RS59850B1 (sr) 2010-04-12 2020-02-28 Reata Pharmaceuticals Inc Bardoksolon metil za lečenje gojaznosti
WO2011140078A1 (en) 2010-05-04 2011-11-10 Concert Pharmaceuticals, Inc. Synthetic triterpenoid derivatives
WO2012009171A2 (en) 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
CN102079772A (zh) 2010-12-09 2011-06-01 中国药科大学 一类五环三萜-13,28-内酯化合物、其制备方法和用途
CN102070697A (zh) 2010-12-09 2011-05-25 中国药科大学 一种齐墩果酸衍生物、其制备方法及用途
NO2651902T3 (es) 2010-12-17 2018-04-07
CA2826113C (en) 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
CN102153613B (zh) 2011-02-28 2013-08-14 贵州省中国科学院天然产物化学重点实验室 夏枯草酸的制备方法和应用
CN102093462B (zh) 2011-02-28 2012-11-21 贵州省中国科学院天然产物化学重点实验室 1α,2α-二羟基齐墩果酸的制备方法和应用
ES2729405T3 (es) 2011-03-11 2019-11-04 Reata Pharmaceuticals Inc Derivados triterpenoides de C4-monometilo y métodos de uso de los mismos
WO2012154554A1 (en) 2011-05-06 2012-11-15 Catabasis Pharmaceuticals, Inc. Fatty acid triterpene derivatives and their uses
CN102250189B (zh) 2011-05-20 2012-08-29 中国药科大学 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途
ES2861393T3 (es) 2012-04-27 2021-10-06 Reata Pharmaceuticals Inc Derivados de 2,2-difluoropropionamida de bardoxolona metilo, composiciones farmacéuticas y polimorfos de los mismos para su uso en el tratamiento de determinadas afecciones
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2013169740A2 (en) 2012-05-08 2013-11-14 Trustees Of Dartmouth College Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
RU2487884C1 (ru) 2012-07-13 2013-07-20 Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями
CN103665087A (zh) 2012-09-03 2014-03-26 上海源力生物技术有限公司 一种萜类化合物及其在医药上的应用
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
EP2892910B1 (en) 2012-09-10 2016-09-07 AbbVie Inc. Glycyrrhetinic acid derivatives with anti-inflammatory activity
EA029174B1 (ru) 2012-09-10 2018-02-28 Рита Фармасьютикалз, Инк. C17-алкандиильные и алкендиильные производные олеаноловой кислоты и способы их применения
ES2644615T3 (es) 2012-09-10 2017-11-29 Reata Pharmaceuticals, Inc. Derivados de heteroarilo C17 del ácido oleanólico y métodos de uso de éstos
WO2014048033A1 (en) 2012-09-28 2014-04-03 Applied Pharmaceutical Science, Inc. Polymorphs of cddo ethyl ester and uses thereof
CN102887936A (zh) 2012-10-24 2013-01-23 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型
CN102875634B (zh) 2012-10-24 2014-08-20 苏州晶云药物科技有限公司 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型
UY35534A (es) 2013-04-24 2014-10-31 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
NZ756256A (en) 2013-08-23 2021-07-30 Reata Pharmaceuticals Inc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
JP6530758B2 (ja) 2014-01-24 2019-06-12 リアタ ファーマシューティカルズ，インク 抗酸化性炎症調節剤としてのアリールおよびアリールアルキル置換されたピラゾリルおよびピリミジニル三環式エノン類
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
JP6633812B2 (ja) 2016-11-08 2020-01-22 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルまたはその類似体を使用してアルポート症候群を処置する方法
CN110248932B (zh) 2016-12-16 2023-03-10 里亚塔医药公司 用于抑制RORγ和其他用途的嘧啶三环烯酮衍生物

Also Published As

Publication number Publication date
PT2841445T (pt) 2017-09-01
PL2841445T3 (pl) 2017-10-31
TW201348245A (zh) 2013-12-01
BR112014026640A2 (pt) 2017-07-18
EA201491972A1 (ru) 2015-02-27
ME02926B (me) 2018-04-20
KR20150003875A (ko) 2015-01-09
IL235275B (en) 2018-03-29
BR112014026640B1 (pt) 2021-05-18
DK3444261T3 (da) 2021-03-08
HK1207085A1 (en) 2016-01-22
HRP20171275T1 (hr) 2017-10-20
US20150259377A1 (en) 2015-09-17
US11078230B2 (en) 2021-08-03
SG11201406868XA (en) 2014-11-27
CY1124130T1 (el) 2022-05-27
TW201726701A (zh) 2017-08-01
US20180009839A1 (en) 2018-01-11
MY172750A (en) 2019-12-11
ES2861393T3 (es) 2021-10-06
MX2014013076A (es) 2015-05-11
PL3444261T3 (pl) 2021-07-19
UA116209C2 (uk) 2018-02-26
PE20150160A1 (es) 2015-02-19
JP2015521166A (ja) 2015-07-27
US20210355156A1 (en) 2021-11-18
ZA201407326B (en) 2016-10-26
SI2841445T1 (sl) 2017-12-29
NZ630222A (en) 2016-06-24
HK1207086A1 (en) 2016-01-22
DK2841445T3 (en) 2017-09-11
CA2869783A1 (en) 2013-10-31
CO7170182A2 (es) 2015-01-28
RS56154B1 (sr) 2017-11-30
ES2634315T3 (es) 2017-09-27
DOP2014000236A (es) 2015-04-30
HUE053113T2 (hu) 2021-06-28
CA2869783C (en) 2022-06-21
WO2013163344A1 (en) 2013-10-31
RS61544B1 (sr) 2021-04-29
EP3444261A1 (en) 2019-02-20
CN104395332B (zh) 2017-01-18
TWI623548B (zh) 2018-05-11
US20130324599A1 (en) 2013-12-05
KR102101774B1 (ko) 2020-04-20
US9701709B2 (en) 2017-07-11
US8993640B2 (en) 2015-03-31
JP6637136B2 (ja) 2020-01-29
PT3444261T (pt) 2021-03-12
EP2841445B1 (en) 2017-06-14
AU2013251602B2 (en) 2017-09-28
AR092823A1 (es) 2015-05-06
CN104395332A (zh) 2015-03-04
EP3444261B1 (en) 2021-01-13
LT2841445T (lt) 2017-09-11
EP2841445A1 (en) 2015-03-04
JP2019011349A (ja) 2019-01-24
UY34764A (es) 2013-11-29
CY1119333T1 (el) 2018-02-14
CL2014002886A1 (es) 2015-02-06
AU2013251602A1 (en) 2014-10-23
EA030468B1 (ru) 2018-08-31
JP6410710B2 (ja) 2018-10-24
LT3444261T (lt) 2021-05-10
SI3444261T1 (sl) 2021-04-30
HUE035673T2 (en) 2018-05-28

Similar Documents

Publication Publication Date Title
MX357060B (es) Derivados de 2,2-difluoropropionamida de bardoxolon metilo, formas polimorficas y metodo para su uso de los mismos.
PH12015502459A1 (en) 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
MX348862B (es) Derivados c4-monometil triterpenoides y sus metodos de uso.
NZ705213A (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
UA117122C2 (uk) Хінолонові похідні
MY180903A (en) C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
WO2016013030A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
WO2013059281A3 (en) Processes for the preparation of novel benzimidazole derivatives
NZ720340A (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
BR112015022509A2 (pt) forma cristalina de cis-(e)-4-(3-fluorofenil)-2',3',4',9'-tetra-hidro-n,n-dimetil-2'-(1-oxo-3-fenil-2-propenil)-espiro[ciclohexano-1,1'[1h]-pirido[3,4-b]indol]-4-amina cristalina
ECSP13013080A (es) Derivados de pirazol útiles como inhibidores de aldosterona sintasa
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
AR124675A2 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
BR112015030591A2 (pt) formas de polimorfos de maleato de icotinib e usos dos mesmos
WO2014153113A3 (en) Processes and intermediates for the preparation of 3 amino-n-cyclopropyl-2 hydroxypropionamide derivatives
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
CR11811A (es) Nuevos derivados de azabiciclo[3.2.0]hept-3-ilo, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
FG Grant or registration